Search results for " Relapse."

showing 10 items of 44 documents

Stem cell functionality is microenvironmentally defined during tumour expansion and therapy response in colon cancer

2018

Solid malignancies have been speculated to depend on cancer stem cells (CSCs) for expansion and relapse after therapy. Here we report on quantitative analyses of lineage tracing data from primary colon cancer xenograft tissue to assess CSC functionality in a human solid malignancy. The temporally obtained clone size distribution data support a model in which stem cell function in established cancers is not intrinsically, but is entirely spatiotemporally orchestrated. Functional stem cells that drive tumour expansion predominantly reside at the tumour edge, close to cancer-associated fibroblasts. Hence, stem cell properties change in time depending on the cell location. Furthermore, although…

0301 basic medicineColorectal cancerCellClone (cell biology)Mice NudeContext (language use)Colon cancer cancer stem cells tumor microenvironment.Article03 medical and health sciencesCancer stem cellCancer Stem CellsAntineoplastic Combined Chemotherapy ProtocolsmedicineTumor MicroenvironmentAnimalsHumansOsteopontin (OPN Spp1)OsteopontinStem Cell DynamicsCells CulturedCell ProliferationbiologyColon CancerGene Expression ProfilingCancerDisease RelapseTumour growthCell Biologymedicine.diseaseXenograft Model Antitumor AssaysCell biologyGene Expression Regulation NeoplasticOxaliplatinTamoxifen030104 developmental biologymedicine.anatomical_structureColonic Neoplasmsbiology.proteinNeoplastic Stem CellsTherapyStem cellCuesNature cell biology
researchProduct

The two faces of tumor-associated macrophages and their clinical significance in colorectal cancer

2019

© 2019 Pinto, Rios, Durães, Ribeiro, Machado, Mantovani, Barbosa, Carneiro and Oliveira. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

0301 basic medicineMaleColorectal cancerprognostic and tumor relapseMacrophages / immunologyhuman macrophage surface markers0302 clinical medicineTumor MicroenvironmentImmunology and AllergyColorectal Neoplasms / mortalityOriginal ResearchAged 80 and overTumor immunomodulationCD68tumor-associated macrophagesTumor-associated macrophagesTumor Microenvironment / immunologyMiddle AgedPrognosis3. Good healthMacrophage polarizationImmunohistochemistryFemaleHuman macrophage surface markerstumor immunomodulationColorectal NeoplasmsInfiltration (medical)lcsh:Immunologic diseases. AllergyAdultmacrophage polarizationImmunologyMacrophage polarizationcolorectal cancerBiologyPrognostic and tumor relapseColorectal Neoplasms / pathology03 medical and health sciencesYoung AdultImmune systemmedicineHumansAgedMacrophagesColorectal Neoplasms / immunologymedicine.diseaseColorectal cancer030104 developmental biologyCancer researchlcsh:RC581-607CD163CD80030215 immunology
researchProduct

The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis

2018

ObjectiveTo evaluate whether the clinical benefit and relapse rates in anti-muscle-specific kinase (MuSK) myasthenia gravis (MG) differ depending on the protocol of rituximab followed. MethodsThis retrospective multicentre study in patients with MuSK MG compared three rituximab protocols in terms of clinical status, relapse, changes in treatment, and adverse side effects. The primary effectiveness endpoint was clinical relapse requiring a further infusion of rituximab. Survival curves were estimated using Kaplan-Meier methods and survival analyses were undertaken using Cox proportional-hazards models. ResultsTwenty-five patients were included: 11 treated with protocol 4 + 2 (375 mg/m(2)/4 w…

0301 basic medicinemedicine.medical_specialtyTime to relapseRelapse rateGastroenterologyAssaigs clínics de medicaments03 medical and health sciencesMalalties del sistema nerviós0302 clinical medicineimmune system diseasesInternal medicineMedicineIn patientRelapse riskAdverse effectSurvival analysisbusiness.industryGeneral NeuroscienceNervous system DiseasesDrug testingmedicine.diseaseMyasthenia gravis030104 developmental biologyRituximabNeurology (clinical)business030217 neurology & neurosurgerymedicine.drug
researchProduct

Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycl…

2009

Background The prevalence of and risk factors for central nervous system recurrence in patients with acute promyelocytic leukemia are not well established and remain a controversial matter. Design and Methods Between 1996 and 2005, 739 patients with newly diagnosed acute promyelocytic leukemia enrolled in two consecutive trials (PETHEMA LPA96 and LPA99) received induction therapy-with all-trans retinoic acid and idarubicin. Consolidation therapy comprised three courses of anthracycline monochemotherapy (LPA96), with all-trans retinoic acid and reinforced doses of idarubicin in patients with an intermediate or high risk of relapse (LPA99). Central nervous system prophylaxis was not given. Re…

:Chemicals and Drugs::Organic Chemicals::Hydrocarbons::Hydrocarbons Cyclic::Hydrocarbons Aromatic::Polycyclic Hydrocarbons Aromatic::Naphthacenes::Anthracyclines::Daunorubicin::Idarubicin [Medical Subject Headings]:Diseases::Pathological Conditions Signs and Symptoms::Pathologic Processes::Disease Attributes::Recurrence [Medical Subject Headings]Male:Named Groups::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings]idarubicinGastroenterology:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [Medical Subject Headings]:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]Central Nervous System NeoplasmsLeukemia Promyelocytic AcuteRecurrenceRisk FactorsCumulative incidenceAntibiotics AntineoplasticHematologyMiddle Agedall-trans retinoic acidLeukemiamedicine.anatomical_structure:Named Groups::Persons::Age Groups::Adolescent [Medical Subject Headings]Femalemedicine.drugAcute promyelocytic leukemiaAdultcentral nervous system relapsemedicine.medical_specialty:Diseases::Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia Myeloid::Leukemia Myeloid Acute [Medical Subject Headings]AnthracyclineAdolescentCentral nervous system:Check Tags::Male [Medical Subject Headings]TretinoinNeoplasias del sistema nervioso centralCentral nervous system diseaseTretinoinInternal medicine:Named Groups::Persons::Age Groups::Adult [Medical Subject Headings]medicineIdarubicinHumans:Named Groups::Persons::Age Groups::Adult::Aged [Medical Subject Headings]Letters to the Editor:Chemicals and Drugs::Organic Chemicals::Hydrocarbons::Hydrocarbons Acyclic::Alkenes::Polyenes::Carotenoids::Retinoids [Medical Subject Headings]Leucemia promielocítica agudaAgedAntibióticos antineoplásicosbusiness.industryprognostic factors:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents::Antibiotics Antineoplastic [Medical Subject Headings]acute promyelocytic leukemiamedicine.diseaseSurgery:Diseases::Neoplasms::Neoplasms by Site::Nervous System Neoplasms::Central Nervous System Neoplasms [Medical Subject Headings]:Check Tags::Female [Medical Subject Headings]businessIdarubicin
researchProduct

Quantification of the risk of relapses after thyroid loboisthmusectomy for benign thyroid nodules

2006

AIM OF THE STUDY: To evaluate correlations between pre-operating epidemiological, clinical and diagnostic data and relapses concerning to patients operated on for benign thyroid nodules. MATERIAL AND METHODS: The AA. carried out a new ultrasonographic exam in 155 patients selected at random among 1012 treated by thyroid lobectomy between September 1976 and December 2002; 107 relapses were found (69%). The obtained data are analysed by chi2 test and a significant correlation between recurrence and data preceding first operation was found: non-homogeneous thyroid structure, multiple nodules, presence of peri-lesional halo, anti-thyroid antibodies, and non-adenomatous histological structure. C…

AdenomaAdultMaleChi-Square DistributionTime FactorsGoiterAge FactorsMiddle AgedGoitre relapse Thyroid lobectomyGraves DiseaseSex FactorsRecurrenceRisk FactorsThyroidectomyHumansFemaleThyroid NeoplasmsThyroid NoduleAgedFollow-Up StudiesGoiter NodularUltrasonography
researchProduct

Laparoscopic surgery for isolated inguinal node relapse of high grade serous ovarian cancer using a bipolar combination instrument

2020

Abstract Objective To demonstrate step-by-step minimally invasive surgical technique for dissection of isolated inguinal node relapse of high grade serous ovarian cancer. Methods A 54-year-old woman, BRCA1 +, underwent to open abdominal total hysterectomy, bilateral salpingo-oophorectomy, total omentectomy, pelvic and aortic lymphadenectomy with zero residual disease, for high grade serous ovarian carcinoma FIGO stage IIB. After surgery, patient underwent platinum-based chemotherapy for six cycles and follow-up examinations every 3 months for the first year and biannual for the second one. Abdominal TC-PET scan after 18 months revealed a right distal iliac external/inguinal nodal relapse (S…

AdultLaparoscopic surgerymedicine.medical_specialtyendocrine system diseasesmedicine.medical_treatmentInguinal CanalOvarian carcinomamedicineHumansMinimally Invasive Surgical ProceduresLaparoscopyOvarian NeoplasmsHysterectomymedicine.diagnostic_testbusiness.industryPrognosismedicine.diseasefemale genital diseases and pregnancy complicationsCystadenocarcinoma SerousSurgerySerous fluidDeep inguinal ringmedicine.anatomical_structureOncologyCancer Inguinal Laparoscopy Ovarian Relapse SurgeryFemaleLaparoscopySurgeryLymphadenectomyNeoplasm Recurrence LocalOvarian cancerbusinessSurgical Oncology
researchProduct

Abortion induces reactivation of inflammation in relapsing-remitting multiple sclerosis

2018

ObjectiveTo investigate clinical and radiological outcomes of women with relapsing-remitting multiple sclerosis (RRMS) undergoing abortion.MethodsAn independent, multicentre retrospective study was conducted collecting data from eight Italian MS centres. We compared the preconception and postabortion annualised relapse rate (ARR) and number of Gadolinium enhancing (Gd+) lesions, by analyses of covariance. Variables associated with postabortion clinical and MRI activity were investigated using Poisson regression models; each abortion was considered as a statistical unit.ResultsFrom 1995 to 2017, we observed 188 abortions (17 elective) in 153 women with RRMS. Abortions occurred after a mean t…

AdultMalemedicine.medical_specialtyMultiple SclerosisGadoliniumNeuroimagingDiseaseRelapsing-RemittingAbortionSettore MED/26annualised relapse rateYoung Adult03 medical and health sciencessymbols.namesakeMultiple Sclerosis Relapsing-Remitting0302 clinical medicineRecurrencemedicineHumansPoisson regressionRetrospective StudiesInflammationPregnancy030219 obstetrics & reproductive medicinebusiness.industryObstetricsMultiple sclerosisInducedAbortionAbortion InducedRetrospective cohort studymedicine.diseaseMagnetic Resonance Imaginggadolinium enhancing lesionDiscontinuationPsychiatry and Mental healthPregnancy Maintenancemultiple sclerosisymbolsSettore MED/26 - NeurologiaFemaleSurgerypregnancyNeurology (clinical)business030217 neurology & neurosurgeryabortion; annualised relapse rate; gadolinium enhancing lesion; multiple sclerosis; pregnancyJournal of Neurology, Neurosurgery & Psychiatry
researchProduct

Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomi…

2006

AIM: To assess the efficacy of different schedules of consensus interferon (CIFN) plus ribavirin in retreating chronic hepatitis C patients who relapsed after recombinant interferon (rIFN) monotherapy. METHODS: Forty-five patients (34 males and 11 females) with chronic hepatitis due to hepatitis C virus (HCV) genotype 1 who relapsed after a previous course of rIFN monotherapy were randomized to receive 9 μg CIFN three times per week for 52 wk (group A, n = 22) or 18 μg CIFN three times per week for 52 wk (group B, n = 23) in combination with ribavirin 800 to 1200 mg daily for 52 wk (according to body weight). Virological response was evaluated at week 24 (EVR), at the end of treatment (ETR)…

AdultMalemedicine.medical_specialtySettore MED/07 - Microbiologia E Microbiologia ClinicavirusesHepacivirusAlpha interferonHepacivirusPharmacologyGastroenterologyAntiviral AgentsDrug Administration Schedulelaw.inventionchemistry.chemical_compoundRandomized controlled triallawInterferonRecurrenceInternal medicineRibavirinmedicineHumansIn patientSettore MED/12 - GastroenterologiabiologyDose-Response Relationship Drugbusiness.industryRibavirinGastroenterologyInterferon-alphaGeneral MedicineHepatitis C ChronicMiddle AgedViral Loadbiology.organism_classificationhumanitiesRecombinant ProteinsTreatment OutcomechemistryInterferon Type IInterferon Ribavirin Hepatitis C virus Hepatitis C RelapserDrug Therapy CombinationFemalebusinessViral loadInterferon type IRapid Communicationmedicine.drugWorld journal of gastroenterology
researchProduct

Recurrence of odontogenic keratocysts and possible prognostic factors : review of 455 patients

2019

Background To describe epidemiological features of 565 Chinese patients with odontogenic keratocysts (OKC), to investigate possible prognostic factors related to recurrence, and to analyse features of recurrent OKC (rOKC). Material and Methods A retrospective chart review of 565 cases of OKC treated between 2003 and 2015 was undertaken. The probability of recurrence related to prognostic factors including large size, cortical perforation combined with involved teeth in the lumen of the cyst, inflammation, sites of the involved lesion, sex, and daughter cyst variables were analysed. The subsequent relapse of each OKC was compared. Results Patients ranged in age from 7 to 81 years (mean age, …

AdultMalemedicine.medical_specialtySubsequent RelapseEnucleationPerforation (oil well)Odontogenic TumorsLesion03 medical and health sciences0302 clinical medicineRecurrenceEpidemiologyHumansMedicineCystGeneral DentistryRetrospective Studiesbusiness.industryResearchRetrospective cohort study030206 dentistryPrognosismedicine.disease:CIENCIAS MÉDICAS [UNESCO]SurgeryOtorhinolaryngologyMaxillaOdontogenic CystsUNESCO::CIENCIAS MÉDICASFemaleSurgeryOral SurgeryNeoplasm Recurrence Localmedicine.symptombusiness
researchProduct

Retrospective, observational, multicentre study on an Italian population affected by chronic hepatitis C who failed to clear HCV-RNA after the combin…

2010

There is a lack of information on the characteristics of patients with chronic hepatitis C virus infection (HCV) who fail to respond to antiviral treatment. We studied HCV-positive subjects with chronic liver diseases treated with pegylated-interferon (PEG-IFN) and ribavirin (RBV) who failed to clear HCV in routine clinical practice. A total of 2150 consecutive adult patients treated with PEG-IFN plus RBV therapy in 46 Italian centres between 1 July 2004, and 30 June 2005, were studied. Of the 2150 patients, 923 (42.9%) (M/F 585/335, mean age 54.8 years) failed to achieve a serum HCV-RNA clearance. Of these 923 patients, 429 (46.5%) were nonresponders, 298 (32.3%) relapsers, 168 (18.2%) dro…

AdultMalenon-responders.relapserGenotypebody mass index; cirrhosis; hepatitis c virus; nonresponder; pegylated-interferon; relapserInfectious Diseasebody mass indexHepacivirusvirusInterferon alpha-2Antiviral AgentsPolyethylene GlycolPolyethylene GlycolsMedication Adherencebody mass index; cirrhosis; hepatitis C; virus; nonresponder; pegylated-interferon; relapserRisk FactorsRetrospective StudienonresponderVirologyRibavirinHumansAge FactorTreatment FailureRetrospective StudiesAgedAntiviral AgentSettore MED/12 - GastroenterologiaHCV; Antiviral therapy; Body mass index; Cirrhosis; Hepatitis C virus; Nonresponder; Pegylated-interferon; RelapserCirrhosiHepaciviruHepatologyRisk FactorcirrhosisAge FactorsInterferon-alphahepatitis c virusHepatitis C ChronicMiddle AgedRecombinant ProteinRecombinant ProteinsItalyRNA ViralFemalehepatitis Cpegylated-interferonHepatitis C viruHuman
researchProduct